Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
News Type
News Topics
- (-) Biomedical (2)
- 3-D Printing/Advanced Manufacturing (5)
- Advanced Reactors (1)
- Artificial Intelligence (3)
- Bioenergy (5)
- Clean Water (1)
- Composites (1)
- Computer Science (8)
- Critical Materials (1)
- Cybersecurity (4)
- Energy Storage (1)
- Environment (4)
- Exascale Computing (1)
- Frontier (2)
- Fusion (2)
- Grid (1)
- Isotopes (1)
- Machine Learning (1)
- Materials Science (8)
- Microscopy (1)
- Nanotechnology (2)
- Neutron Science (6)
- Nuclear Energy (2)
- Physics (2)
- Quantum Science (5)
- Security (2)
- Space Exploration (1)
- Summit (3)
- Sustainable Energy (5)
- Transportation (2)
Media Contacts
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.
OAK RIDGE, Tenn., March 4, 2019—A team of researchers from the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute have harnessed the power of artificial intelligence to better match cancer patients with clinical trials.